FDA and state rules, for what you actually buy.

Must a pharmacy located in another state hold a license/registration from this state to ship prescriptions (including patient-specific 503A compounded preparations) to patients or practitioners here?

59 O.S. §353.18(A) makes it unlawful to sell or offer dangerous drugs at retail, or to accept prescriptions, without a Board of Pharmacy license, including when the sale happens out of state and the drug is delivered into Oklahoma. Under OAC 535:15-3-9, a non-resident pharmacy needs: an annual non-resident license; a resident-state license in good standing; an inspection report from the past 24 months by its home state or a Board-approved organization, at first licensure and at every renewal; a commercial (non-residential) location; and toll-free pharmacist counseling. It must name a pharmacist-in-charge licensed both in its home state and by Oklahoma, who must be on site at least 20 hours a week. Oklahoma law applies to the Oklahoma part of its operation, and the Board may inspect it on site at the pharmacy's expense. A non-resident pharmacy that compounds sterile preparations must also hold a sterile compounding permit, renewed with its non-resident license (OAC 535:15-9-3, 15-9-4).

The source is the Board's own unofficial compilation of statute and rules (July 2026); the official text is at rules.ok.gov (not fetched). Oklahoma requires an Oklahoma-licensed PIC; a 90-day extension is possible in urgent situations. The fee is $150 per year for a non-resident pharmacy license and $75 for a sterile compounding permit.

May a 503A (traditional) pharmacy dispense or distribute compounded preparations to a practitioner for office use (administration in the office, not patient-specific)? The federal position is that 503A requires patient-specific prescriptions; this is what the state pharmacy act and board rules allow.

OAC 535:15-7 defines a 'drug supplier' as a licensed retail pharmacy that supplies legend drugs to licensed prescribers for office administration. It requires a Drug Supplier Permit and a valid retail pharmacy license. These sales may not exceed 5% of the pharmacy's total annual sales, and separate invoice records are required. The compounding rules (535:15-10) tie compounding to a prescriber's prescription or order and to anticipatory batches based on regular prescribing patterns. They state an office-use allowance without patient-specific prescriptions only for animal drugs (535:15-10-13). Board inspection forms check 'Office-use meds sold per invoice w/DS permit' (retail form, July 2025) and 'Preparing "For Office Use"' / 'Office Use properly labeled' (compounding form, 2014), which shows the Board inspects office-use supply. Because the permit is open only to Oklahoma retail pharmacies, a non-resident pharmacy has no stated route to ship office stock into Oklahoma. In-state office stock without a patient-specific prescription goes beyond FDA's 503A position.

The rules say nothing express about human office-use compounding; whether compounded preparations fall under the Drug Supplier Permit is inferred from the definitions and the Board inspection forms, so confirm with the Oklahoma Board of Pharmacy (405-521-3815). The compounding inspection form is from 2014, so it is possibly stale. Retail pharmacies may not supply compounded preparations to wholesalers, outsourcing facilities or other distributors (535:15-7-3).

Does the state require an FDA-registered 503B outsourcing facility located outside the state to hold a state license/registration (as an outsourcing facility, nonresident manufacturer, wholesaler or pharmacy) before shipping into the state?

59 O.S. §353.18(B) makes it unlawful to manufacture, distribute or 'outsource' dangerous drugs without a Board license. This applies when the activity occurs out of state for delivery to patients or customers in Oklahoma. An outsourcing facility must name, in writing, a pharmacist-in-charge licensed by the Oklahoma Board. OAC 535:20-6-3 bars shipping an outsourcing facility's drugs into Oklahoma unless each of its facilities is licensed in Oklahoma, renewed each year, and FDA-registered. Applicants must supply ownership details, background checks and fingerprinting of designated representatives, and proof of FDA and home-state licensure. The Board inspects before licensure (non-residents pay the costs) and may use NABP for inspections. An outsourcing facility that also fills patient-specific prescriptions for Oklahoma must additionally hold an Oklahoma pharmacy or non-resident pharmacy license. Shipments may go only to the address on the recipient's license.

The fee is $200 per year. Each PIC may serve only one facility or pharmacy and must be on site at least 20 hours a week; a non-resident facility may ask for more time for a new PIC to get Oklahoma licensure in urgent situations (535:20-6-6). Taken from the Board's unofficial July 2026 compilation; the official text is at rules.ok.gov.

Has the state signed FDA's standard Memorandum of Understanding Addressing Certain Distributions of Compounded Human Drug Products (October 2020)? If not, FD&C Act §503A limits its 503A pharmacies' out-of-state distribution to 5% of total prescription orders (currently not enforced by FDA pending rulemaking).

Signing the standard MOU means the state board agrees to investigate complaints about compounded drugs its 503A pharmacies ship out of state and to identify and report to FDA pharmacies that distribute "inordinate amounts" interstate (more than 50% of their compounded prescriptions); in exchange, the statutory 5% out-of-state cap in FD&C Act §503A(b)(3)(B) does not apply to that state's pharmacies. FDA lists only Colorado, Kentucky and New Hampshire as signatories; Oklahoma is not among them. For a non-signing state, FD&C Act §503A(b)(3)(B)(ii) caps a 503A pharmacy's out-of-state distribution of compounded drugs at 5% of its total prescription orders. FDA now considers the October 2020 standard MOU suspended (it does not expect signatory states to carry out MOU activities and will not sign new ones) and is not enforcing the 5% limit until a final rule and an updated MOU are published; FDA's rulemaking (RIN 0910-AI71) listed a proposed rule for 11/2026 in the Fall 2025 Unified Agenda.

The FDA list of signed MOUs (current as of 2023-01-23) is older than 2 years, but FDA stopped entering new agreements under the 2020 MOU in October 2022, so no state can have signed since. The FDA "Compounding Information for States" page (current as of 2026-08-28) still describes the MOU as awaiting rulemaking. Pending: FDA proposed rule on 503A distribution (RIN 0910-AI71, NPRM projected 11/2026); H.R. 5316 (introduced 2025-09-11, referred to House Energy & Commerce) would remove the MOU provision from §503A.

Besides DEA registration, does the state require practitioners to hold a separate state controlled substance registration, license or permit to prescribe, administer or dispense controlled substances (e.g. testosterone, Schedule III)? "Conditional" means a state registration is needed only in some settings, such as keeping controlled-substance stock in the office.

63 O.S. 2-302(A) requires every person who manufactures, distributes, dispenses, prescribes, administers or uses for scientific purposes any controlled dangerous substance 'within or into this state' to obtain a registration issued by the OBNDD Director. A separate registration is required at each principal place of business or professional practice where the applicant prescribes, administers or dispenses (2-302(J)), and a professional license is a prerequisite (2-302(L)). Practitioner registrations run for a period set by the Director of one to three years (2-302(F)); licensing boards, including boards of mid-level practitioners, report their licensees to OBNDD each year. Registered and practical nurses acting under a practitioner are exempt (2-302(H)).

The phrase 'within or into this state' means out-of-state telehealth prescribers sending CDS prescriptions into Oklahoma fall under the requirement. OBNDD's website blocked automated access, so the current fee, term and application order relative to DEA were not confirmed; 2-302(M) (registrations issued November 1, annual) and 2-302(F) (term set by the Director, one to three years) read differently - check with OBNDD. Covers NPs and PAs (mid-level practitioners) as well as physicians.

Must a prescriber query the state Prescription Drug Monitoring Program before prescribing, and does the mandate cover Schedule III drugs such as testosterone? "Yes" means a mandate that reaches Schedule III; "conditional" means a mandate limited to certain drugs (e.g. opioids or benzodiazepines) or situations; "no" means no prescriber query mandate.

63 O.S. Sec. 2-309D(G)(2) requires registrants or their staff, before prescribing or authorizing a refill of opiates, synthetic or semisynthetic opiates, benzodiazepines or carisoprodol for a patient of record, to access the central repository if 180 days have elapsed since the previous check, and to note the check in the patient file. It does not apply to hospice or end-of-life care or to prescriptions for residents of nursing facilities. Failure to check can be grounds for discipline by the registrant's licensing board, which has sole enforcement responsibility; the PMP is run by the Oklahoma Bureau of Narcotics and Dangerous Drugs Control.

Source older than 2 years - possibly stale; last amended Laws 2022, SB 1151, emerg. eff. April 25, 2022, and this is the current OSCN text. PDMP TTAC also lists 63 O.S. 2-309I (opioid prescribing limits) and OAC 510:5-3-3.

May physicians dispense prescription drugs (not just administer them) directly to patients from their practice? "Yes" means allowed under standard rules (labeling, records, and at most a simple notice to the board); "conditional" means a separate dispensing registration, permit or license, or quantity, day-supply or drug-category limits; "no" means prohibited except narrow exceptions.

A vendor summary reports that Oklahoma physicians may dispense in the normal course of practice once registered with the Oklahoma State Board of Medical Licensure and Supervision as a dispensing physician (no charge), and that Schedule II-V drugs dispensed from the office must be reported to the Oklahoma PMP in real time (within five minutes). The statute and rule text were not reviewed.

Confirm with the Oklahoma medical board (and the osteopathic board for DOs).

For a patient located in the state: must the prescriber hold this state's license (or a telehealth registration or special license), is an in-person exam required before prescribing (generally or for controlled substances), are there state limits on prescribing Schedule III drugs such as testosterone by telehealth, and is the state an Interstate Medical Licensure Compact member? "Yes" means a state license and the in-person standard of care apply (opioid-only or Schedule II-only limits are described but do not change the answer); "conditional" means extra state conditions such as a telehealth registration route, an in-person exam requirement, controlled-substance limits reaching Schedule III, or registration of telehealth businesses. Federal DEA rules apply on top.

(1) Physicians treating patients in Oklahoma through telemedicine must be fully licensed in Oklahoma, and a relationship may be established by telemedicine only if the physician holds an Oklahoma license, confirms the patient's identity and location and discloses credentials (59 O.S. 478.1; OAC 435:10-7-13). (2) The Board's face-to-face encounter requirement is satisfied by a telemedicine exam using interactive real-time audio and video that provides information equivalent to an in-person exam (OAC 435:10-7-12, 435:10-7-13). (3) Telemedicine may not be used to establish a relationship for prescribing opiates (including synthetic and semisynthetic), benzodiazepines or carisoprodol, except opioid antagonists or partial agonists and FDA-approved Schedule III-V drugs for MAT or detoxification; no Oklahoma telehealth limit reaches testosterone. (4) IMLC: member.

Borderline under the classification rule: the telemedicine limit reaches opioids plus Schedule IV benzodiazepines and carisoprodol, but not testosterone or non-opioid Schedule III drugs, so it was treated as 'yes'. Board rules date from 2014-2015 and are the current text. The statute covers allopathic and osteopathic physicians.

Who may administer botulinum toxin and dermal fillers (physicians, PAs, NPs, RNs, LPNs, estheticians, dentists), under what supervision (on-site vs available), and must a physician/NP/PA perform a prior good-faith exam?

Oklahoma Board of Nursing Guideline P-25 on cosmetic/aesthetic dermatological procedures (approved 2026-03-24, revised 2026-05-19) covers neuromodulator and dermal filler injections, lasers and light treatments. RNs need no on-site physician, APRN or PA if there is a valid individualized order and a completed history and physical by the prescriber; standing orders are not an appropriate substitute, and physicians must establish the relationship through an initial evaluation, face to face or by telemedicine. LPNs may perform these procedures under supervision by an RN, physician or dentist on the same conditions. Nurses need documented competency, and settings must keep on-site procedure and emergency policies.

What does the state require for elective IV hydration/vitamin (incl. NAD+) therapy: who may start IVs, is a patient-specific order or good-faith exam required before a patient's first IV, are standing orders allowed, and are there rules for mobile IV services?

Oklahoma Board of Nursing Guideline P-24 on IV hydration (approved 2026-03-24, revised 2026-05-19) applies to walk-in and mobile hydration clinics and drip bars. RNs do not need a physician, APRN or PA on site if there is a valid individualized order and a completed history and physical by the prescriber; standing orders are not an appropriate substitute, and physicians must establish the relationship through an initial evaluation, face to face or by telemedicine. LPNs may administer under RN, physician or dentist supervision if they meet the Board's LPN IV medication guideline.

Does the state enforce the corporate practice of medicine doctrine (non-physicians may not own medical practices or employ physicians), and how does that affect med spa ownership?

Permit Health's 2025 guide lists Oklahoma among non-CPOM states, citing Okla. Stat. tit. 18 §844 and Attorney General Opinion No. 77-168; MedPath Compliance (reviewed 2026-06-20) also lists Oklahoma as 'No'. Laser hair removal facilities must nonetheless be overseen by a physician, PA or APRN under the Laser Hair Removal Act.

Who may perform laser/IPL/RF aesthetic procedures (laser hair removal, resurfacing): physicians only, delegated to RNs/PAs, or licensed electrologists/estheticians/laser technicians with state certification?

Under 59 O.S. §538.3, only FDA-approved lasers or pulsed-light devices for noninvasive procedures may be used; a person must hold an appropriate health professional licence or be a laser practitioner supervised by a physician, certified PA or certified APRN, and non-physician laser practitioners must complete a 40-hour training program overseen by a physician. Each laser hair removal facility must be overseen by a physician, PA or APRN who sets written protocols (including complication management by a physician, PA or APRN), decides how many practitioners they supervise and reviews at least 10% of patient records; the physician, PA or APRN must perform an initial evaluation of each patient, face to face or by telemedicine. The Board of Nursing's P-25 guideline also lets RNs perform aesthetic laser procedures on an individualized order after the prescriber's history and physical.

Statute page shows 'OSCN 2026' with no enactment date on the fetched text.

Does the state license clinical laboratories itself, beyond federal CLIA certification, including out-of-state labs that test specimens from the state?

Most states rely on federal CLIA certification alone. The states confirmed in this research as issuing their own lab licenses are California, New York, Pennsylvania, Maryland and Rhode Island (which also reach out-of-state labs testing specimens from their residents), plus Nevada, Washington, Massachusetts, New Jersey and New Hampshire (labs located in the state). Oklahoma was not among them, but this research did not confirm its statutes. Oklahoma's CLIA state agency is Oklahoma State Dept. of Health, Protective Health Services (clia@health.ok.gov, 405-426-8470); it can confirm whether any state license or permit applies, including to out-of-state labs.

Absence of a state license was not verified against the state's statutes or rules.

May consumers order their own lab tests without a practitioner order (direct access testing)? A practitioner-ordered panel is always fine; this matters for take-home and consumer test kits.

ADLM (formerly AACC) reported in 2019 that 37 states and DC let consumers order some or all tests directly, but it did not publish the state list, and this research did not confirm Oklahoma's rule. Oklahoma's lab regulator (CLIA state agency) is Oklahoma State Dept. of Health, Protective Health Services (clia@health.ok.gov, 405-426-8470). The question matters for take-home and consumer test kits, not for panels a clinician orders.

The ADLM figure dates from 2019 (older than 2 years).

Has the state enacted a law or rule specifically about stem cell, exosome or regenerative-medicine therapies (notice/disclosure duties, permission for certain non-FDA-approved uses, or Right to Try extensions covering them)?

Compilations of state stem-cell laws from 2024 to 2026 list about a dozen states with specific laws (California, Florida, Georgia, Mississippi, Nevada, North Carolina, Tennessee, Texas, Utah, Vermont, Washington and Wyoming), plus Montana's general experimental-treatment law and Kansas's state stem cell center. Oklahoma is not among them. Without a state-specific law, regenerative products are governed by federal FDA rules plus the state's general medical practice, advertising and consumer-protection laws, enforced by its medical board. Federal FDA rules still apply regardless of state law: stem cell, birth-tissue and exosome products are regulated by FDA, and a state law cannot make an unapproved biologic FDA-approved.

The finding of no law rests on multi-state compilations (a commercial one from Aug 2026 and a peer-reviewed one from Feb 2024, which is older than 2 years) and targeted searches, not a statute-by-statute review, and neither compilation is exhaustive. General Right to Try laws for terminal patients, where they exist, were not reviewed here.

Does the state have cosmetic or sunscreen requirements beyond federal MoCRA, such as ingredient bans (PFAS, formaldehyde, phthalates), ingredient reporting, sunscreen-ingredient bans, or bans on selling animal-tested cosmetics?

Oklahoma does not appear on 2026 compilations of state PFAS-in-cosmetics laws, on the list of states banning animal-tested cosmetics, or among the jurisdictions with sunscreen-ingredient bans. Federal MoCRA and FDA rules on cosmetics and OTC sunscreens still apply. Other state laws that touch cosmetics generally, such as state food-drug-cosmetic acts or consumer-protection laws, were not surveyed.

The animal-testing list is Wikipedia's 'as of 2023' compilation (older than 2 years); effective dates were not confirmed.